Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Jansen

Showing results (91-100 of 108) with videos related to

Pageof 11
Sort By:
Scientific Reports|March 21, 2026
Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational studyTobias Eckert, Martin Aursand Berge, Michael Long, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2019
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networksRoman C Maron, Michael Weichenthal, Jochen S Utikal, et al.
Trials|January 17, 2026
Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristicsGavin Brittain, Ellen Buckley, Vita Lanfranchi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
The International Journal of Behavioral Nutrition and Physical Activity|November 22, 2025
Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?Joren Buekers, Julia Chernova, Sarah Koch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Annals of the American Thoracic Society|September 23, 2024
Validation of the Late-Life Function and Disability Instrument in People Living with COPDAstrid Blondeel, Heleen Demeyer, Victoria Alcaraz-Serrano, et al.
The European Respiratory Journal|May 22, 2025
How do people with COPD walk? A European study on digitally measured real-world gaitLaura Delgado-Ortiz, Joren Buekers, Nikolaos Chynkiamis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Pageof 11

Showing results (91-100 of 108) with videos related to

Sort By:
Pageof 11
Scientific Reports|March 21, 2026
Construct validity of real-world digital mobility outcomes in patients after proximal femoral fracture: a cross-sectional observational studyTobias Eckert, Martin Aursand Berge, Michael Long, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2019
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networksRoman C Maron, Michael Weichenthal, Jochen S Utikal, et al.
Trials|January 17, 2026
Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristicsGavin Brittain, Ellen Buckley, Vita Lanfranchi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomasPhilipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
The International Journal of Behavioral Nutrition and Physical Activity|November 22, 2025
Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed?Joren Buekers, Julia Chernova, Sarah Koch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapyCarl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Characterisation and outcome of RAC1 mutated melanomaGeorg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Annals of the American Thoracic Society|September 23, 2024
Validation of the Late-Life Function and Disability Instrument in People Living with COPDAstrid Blondeel, Heleen Demeyer, Victoria Alcaraz-Serrano, et al.
The European Respiratory Journal|May 22, 2025
How do people with COPD walk? A European study on digitally measured real-world gaitLaura Delgado-Ortiz, Joren Buekers, Nikolaos Chynkiamis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitorsCarl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Pageof 11